Imricor Medical Systems (ASX:IMR) reported a total revenue of $132,000 for the March quarter, with its consumables revenue of $104,000 up 385% year-over-year, according to a Wednesday Australian bourse filing.
The firm reported net cash inflows from financing activities of $43 million in the March quarter, comprising net proceeds from the completion of the placement. Meanwhile, its net cash outflows from operating activities came in at $4.6 million.
It also established Imricor BV, a wholly-owned subsidiary in the Netherlands, during the quarter. It hired the first capital sales managers in the US in preparation for a US commercial launch.
On April 10, the first-in-man ventricular ablation guided by real-time interventional cardiac magnetic resonance was performed at the Amsterdam University Medical Centre.
Its shares rose 5% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。